Lipid-based liquid crystalline nanoparticles as oral drug delivery vehicles for poorly water-soluble drugs: Cellular interaction and in vivo absorption

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 3703-3718

  Zeng, Ni ^a,c   Gao, Xiaoling ^b   Hu, Quanyin ^a   Song, Qingxiang ^b   Xia, Huimin ^a   Liu, Zhongyang ^a   Gu, Guangzhi ^a   Jiang, Mengyin ^a,d   Pang, Zhiqing ^a   Chen, Hongzhuan ^b   Chen, Jun ^a   Fang, Liang ^c  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^d SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Cellular interaction; Glycerol dioleate; Liquid crystalline nanoparticles; Paclitaxel; Soy phosphatidylcholine

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; LIPID BASED LIQUID CRYSTALLINE NANOPARTICLE; NANOPARTICLE; PACLITAXEL; PHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL INTERACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG RELEASE; DRUG SOLUBILITY; ENDOCYTOSIS; FIELD EMISSION SCANNING ELECTRON MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; LASER MICROSCOPY; MALE; NONHUMAN; PARTICLE SIZE; RADIATION SCATTERING; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; CACO-2 CELLS; CELL MEMBRANE; CELL SURVIVAL; DIGLYCERIDES; DRUG CARRIERS; ENDOCYTOSIS; HUMANS; MALE; MEMBRANE FLUIDITY; NANOPARTICLES; OXAZINES; PACLITAXEL; PARTICLE SIZE; PHOSPHATIDYLCHOLINES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 84870367372     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S32599     Document Type: Article

References (42)

1. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004;58:173-182.
2. Varma MV, Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci. 2005;25:445-453.
3. Malingré MM, Meerum Terwogt JM, Beijnen JH, etal. Phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol. 2000;18: 2468-2475.
4. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590-1598.
5. Yang S, Gursoy RN, Lambert G, Benita S. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res. 2004;21:261-270.
6. Ma X, Wang H, Jin S, Wu Y, Liang XJ. Construction of paclitaxel-loaded poly (2-hydroxyethyl methacrylate)-g-poly (lactide)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine copolymer nanoparticle delivery system and evaluation of its anticancer activity. Int J Nanomedicine. 2012;7:1313-1328.
7. Yang D, Van S, Jiang X, Yu L. Novel free paclitaxel-loaded poly(L-γ-glutamylglutamine)-paclitaxel nanoparticles. Int J Nanomedicine. 2011;6:85-91.
8. Roger E, Lagarce F, Garcion E, Benoit JP. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J Control Release. 2009;140:174-181.
9. Lee SC, Kim C, Kwon IC, Chung H, Jeong SY. Polymeric micelles of poly(2-ethyl-2-oxazoline)-block-poly(ε-caprolactone) copolymer as a carrier for paclitaxel. J Control Release. 2003;89:437-446.
10. Yaghmur A, Michael R. Liquid crystalline nanoparticles as drug nanocarriers. Available at: http://www.ibr.oeaw.ac.at/people/Michael/Rappolt_Publ-Dateien/MR2010_5.pdf. Accessed May 31, 2012.
11. Yang D, Armitage B, Marder SR. Minireviews cubic liquid-crystalline nanoparticles. Angew Chem Int Ed Engl. 2004;43:4402-4409.
12. Yaghmur A, Glatter O. Characterization and potential applications of nanostructured aqueous dispersions. Adv Colloid Interface Sci. 2009;147-148:333-342.
13. Efrat R, Aserin A, Kesselman E, Danino D, Wachtel E, Garti N. Liquid micellar discontinuous cubic mesophase from ternary monoolein/ethanol/water mixtures. Colloids Surf A Physiochem Eng Asp. 2007;299:133-145.
14. Lee KWY, Nguyen TH, Hanley T, Boyd BJ. Nanostructure of liquid crystalline matrix determines in vitro sustained release and in vivo oral absorption kinetics for hydrophilic model drugs. Int J Pharm. 2009;365:190-199.
15. Kaasgaard T, Drummond CJ. Ordered 2-D and 3-D nanostructured amphiphile self-assembly materials stable in excess solvent. Phys Chem Chem Phys. 2006;8:4957-4975.
16. Rosenbaum E, Tavelin S, Johansson LB. A characterisation study on the application of inverted lyotropic phases for subcutaneous drug release. Int J Pharm. 2010;388:52-57.
17. Cervin C, Vandoolaeghe P, Nistor C, Tiberg F, Johnsson M. A combined in vitro and in vivo study on the interactions between somatostatin and lipid-based liquid crystalline drug carriers and bilayers. Eur J Pharm Sci. 2009;36:377-385.
18. Johnsson M, Barauskas J, Norlin A, Tiberg F. Physicochemical and drug delivery aspects of lipid-based liquid crystalline nanoparticles: a case study of intravenously administered propofol. J Nanosci Nanotechnol. 2006;6:3017-3024.
19. Rizwan SB, Assmus D, Boehnke A, etal. Preparation of phytantriol cubosomes by solvent precursor dilution for the delivery of protein vaccines. Eur J Pharm Biopharm. 2011;79:15-22.
20. Lai J, Chen J, Lu Y, etal. Glyceryl monooleate/poloxamer 407 cubic nanoparticles as oral drug delivery systems: I. in vitro evaluation and enhanced oral bioavailability of the poorly water-soluble drug simvastatin. AAPS Pharm Sci Tech. 2009;10:960-966.
21. Batrakova EV, Li S, Vinogradov SV, Alakhov VY, Miller DW, Kabanov AV. Mechanism of Pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther. 2001;99:483-493.
22. Gao X, Wang T, Wu B, etal. Quantum dots for tracking cellular transport of lectin-functionalized nanoparticles. Biochem Biophys Res Commun. 2008;377:35-40.
23. Rizwan SB, Dong YD, Boyd BJ, Rades T, Hook S. Characterisation of bicontinuous cubic liquid crystalline systems of phytantriol and water using cryo field emission scanning electron microscopy (cryo-FESEM). Micron. 2007;38:478-485.
24. Barauskas J, Cervin C, Jankunec M, etal. Interactions of lipid-based liquid crystalline nanoparticles with model and cell membranes. Int J Pharm. 2010;391:284-291.
25. Angelova A, Angelov B, Mutafchieva R, Lesieur S, Couvreur P. Self-assembled multicompartment liquid crystalline lipid carriers for protein, peptide, and nucleic acid drug delivery. Acc Chem Res. 2011;44:147-156.
26. Siekmann B, Bunjes H, Koch MHJ, Westesen K. Preparation and structural investigations of colloidal dispersions prepared from cubic monoglyceride-water phases. Int J Pharm. 2002;244:33-43.
27. Boyd BJ, Khoo SM, Whittaker DV, Davey G, Porter CJH. A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. Int J Pharm. 2007;340:52-60.
28. Boyd BJ. Controlled release from cubic liquid-crystalline particles (cubosomes). In: Lynch ML, Spicer PT, editors. Bicontinuous Liquid Crystals. Boca Raton, FL: CRC Press Inc; 2005.
29. Boyd BJ. Characterisation of drug release from cubosomes using the pressure ultrafiltration method. Int J Pharm. 2003;260:239-247.
30. Garg G, Saraf S, Saraf S. Cubosomes: an overview. Biol Pharm Bull. 2007;30:350-353.
31. Shen H, Crowston JG, Huber F, Saubern S, McLean KM, Hartley PG. The influence of dipalmitoyl phosphatidylserine on phase behaviour of and cellular response to lyotropic liquid crystalline dispersions. Biomaterials. 2010;31:9473-9481.
32. Tenchov BG, MacDonald RC, Siegel DP. Cubic phases in phosphatidylcholine-cholesterol mixtures: cholesterol as membrane "fusogen". Biophys J. 2006;91:2508-2516.
33. Greenspan P, Mayer EP, Fowler SD. Nile red: a selective fluorescent stain for intracellular lipid droplets. J Cell Biol. 1985;10:965-973.
34. Xiao L, Xiong X, Xiong X, etal. Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles. Biomaterials. 2011;32:5148-5157.
35. Lamprecht A, Benoit JP. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J Control Release. 2006;112:208-213.
36. Roger E, Lagarce F, Garcion E, Benoit JP. Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells. Eur J Pharm Sci. 2010;40:422-429.
37. Xu P, Gullotti E, Tong L, etal. Intracellular drug delivery by poly (lactic-co-glycolic acid) nanoparticles. Mol Pharm. 2009;6:190-201.
38. Jacobson K, Mouritsen OG, Anderson RGW. Lipid rafts: at a crossroad between cell biology and physics. Nat Cell Biol. 2007;9:7-14.
39. Orlandi PA, Fishman PH. Filipin-dependent inhibition of cholera toxin: evidence for toxin internalization and activation through caveolae-like domains. J Cell Biol. 1998;141:905-915.
40. Garmann D, Warnecke A, Kalayda GV, Kratz F, Jaehde U. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells. J Control Release. 2008;131:100-106.
41. Chiu YL, Ho YC, Chen YM, etal. The characteristics, cellular uptake and intracellular trafficking of nanoparticles made of hydrophobically-modified chitosan. J Control Release. 2010;146:152-159.
42. Xiao L, Xiong X, Xiong X, etal. Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles. Biomaterials. 2011;32:5148-5157.